Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ADH1B | P00325 | 3/20 | 0.48 |
| ▸ | ADH1A | P07327 | 3/20 | 0.48 |
| ▸ | ADH7 | P40394 | 3/20 | 0.48 |
| ▸ | ADH1C | P00326 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ADH4 | P08319 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8176277 | 0.96 | CYP1A2 (0.52) | CYP1A2ADH1BADH1AADH7ADH1C | |
| SCHEMBL5528695 | 0.94 | ADH1B (0.50) | CYP1A2ADH1BADH1AADH7ADH1C | |
| SCHEMBL11788415 | 0.94 | ADH1B (0.50) | CYP1A2ADH1BADH1AADH7ADH1C | |
| SCHEMBL1938229 | 0.88 | GAA (0.50) | CYP1A2ADH1BADH1AADH7ADH1C | |
| SCHEMBL25030595 | 0.87 | CYP1A2 (0.43) | CYP1A2ADH1BADH1AADH7ADH1C | |
| SCHEMBL8636181 | 0.84 | CYP1A2 (0.59) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL16948556 | 0.82 | CYP1A2 (0.53) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL5649769 | 0.82 | TSHR (0.58) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL17814943 | 0.81 | CYP1A2 (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL23876838 | 0.80 | DGKA (0.43) | ADH1BADH1AADH7ADH1CEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021224040-A1 | CONDENSED ISOXAZOLINE DERIVATIVES AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2021-11-11 | — | — | WO | disclosed |
| WO-2020032252-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP | 山口 晃史 | 2020-02-13 | — | — | WO | disclosed |
| CN-101193895-B | Method for producing tricyclic ketone | YAKULT HONSHA KK | 2011-06-01 | — | — | CN | disclosed |
| EP-2149561-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
| CN-101193895-A | Method for producing tricyclic ketone | YAKULT HONSHA KK (JP) | 2008-06-04 | — | — | CN | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
| EP-0676961-A1 | USE OF MACROLIDES FOR THE TREATMENT OF CEREBRAL ISCHEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-4139390-A | Presensitized printing plate having a print-out image | EASTMAN KODAK COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | CYP1A2 1013/4885ADH1B 4462/4885ADH1A 2018/4885 |
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | CYP1A2 877/4885ADH1B 2746/4885ADH1A 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.